Contact Center Industry News

TMCNet:  PeptiMed Signs Agreement with the National Cancer Institute to Assess Safety of HelpTM Drug Delivery Nanoparticle Formulations

[June 23, 2014]

PeptiMed Signs Agreement with the National Cancer Institute to Assess Safety of HelpTM Drug Delivery Nanoparticle Formulations

MADISON, Wisc. --(Business Wire)--

PeptiMed announced today that under a Material Transfer Agreement it will collaborate with the National Cancer Institute's (NCI) Nanotechnology Characterization Laboratory (NCL), located at the Frederick National Laboratory of Cancer Research in Frederick, MD. Under the terms of the Agreement, PeptiMed will provide the NCL with nanocomplex consisting of its proprietary siRNA and patented elastin-like polypeptides (ELPs), and NCL personnel will measure material properties indicative of safety and efficacy for potential future dosing in the clinic.

The nanocomplex materials to be provided by PeptiMed will harbor motifs that bind to cell adhesion molecules on the surface of cancer cells and deliver an siRNA payload that silences the oncogene, EVI1. Initially, the NCL will assess the physical and chemical properties of the nanocomplexes followed by their purity and sterility in cell culture models. A second phase of testing for various modes of toxicity may be performed in animl models.

"We are profoundly pleased to work with the NCL to further our understanding of PeptiMed nanomaterials," stated Scott Schneider, CEO and co-founder of PeptiMed. "We are indeed fortunate to be able to rely on the expertise of the professionals at the NCL to get one step closer to the clinic."

PeptiMed co-founder Dr. Jeremy Heidel added, "The NCL has a strong track record in assisting biotech companies [as well as government and academic institutions] with evaluation and development of novel nanoparticle drug delivery systems. The comprehensive battery of measurements to be performed at the NCL will provide data and analytical methods that will help advance our nanoparticle technology toward the clinic."


The mission of PeptiMed is to discover and provide nucleotide-based therapies and delivery systems for nucleotide-based drugs with unprecedented potency in ameliorating late-stage cancer while avoiding debilitating side effects, thereby improving prognosis and quality of life for each patient. PeptiMed has patented the hELPTM nanoparticle delivery system for nucleotides. PeptiMed plans to begin first-in-human studies to determine maximum tolerated and efficacious doses of the EVIRNATM/hELPTM nanocomplex by the end of FY2015.

This press release contains positive forward-looking statements concerning the therapeutic value of PeptiMed's EVIRNATM/hELPTM nanocomplex. For further information please view the website or contact Dr. Thomas Primiano, Chief Business Officer.

[ Back To Cloud Contact Center's Homepage ]


Featured Resources

Featured Report
Millennial Research on Customer Service Expectations

Millennial Research on Customer Service Expectations

The "why" behind this research is simple: our clients recognize that different generations bring different expectations, varied communication preferences and new customer service patterns to the customer experience...
Featured Report
Optimizing the Customer Experience through Cloud Contact Centers

Optimizing the Customer Experience through Cloud Contact Centers

Adoption of cloud contact centers is on the rise. Findings from Aberdeen's January 2014 'Public Cloud vs. On-Premise: How to More Effectively Deploy a Cloud Center' study shows that 31% of contact centers are deployed in the cloud, and our related blog post highlights that companies anticipate their adoption of cloud technology to rise further throughout 2014...
Featured Report
Aberdeen report

Aberdeen Report: Cloud for Mid-Sized Contact Centers – What You Must Know

Cloud Technology is opening new doors for many businesses. However, it does so only when it's combined with the use of best practices and key technology enablers. This document highlights the adoption of cloud technology by mid-size contact centers and illustrates the reasons driving their investments...
Featured Whitepaper
Aberdeen report

Seven Critical Capabilities to Demand From Your Cloud Contact Center Provider

To deliver a world-class customer experience, your contact center must be flexible and reliable, while providing all the tools agents and supervisors need to manage their workflows. Here are seven critical capabilities to look for when deploying a contact center in the cloud...
Featured Webinar

Contact Center Economics and the Cloud

Together, Bob and Drew will help you understand the economic value of upgrading technology, important business and financial considerations, and how to compare total cost of ownership of a premises vs. cloud or hosted solution. Watch the webinar on-demand now...
Featured Datasheet
Zipwire Cloud Contact Center

Zipwire Cloud Contact Center

The appeal of moving services to the cloud is obvious. Cloud services offer reliability and robust feature sets without the need to implement or maintain complex contact center infrastructure. The Zipwire™ cloud-based contact center allows businesses to leverage the flexibility and cost savings of cloud architecture while offering a seamless, first-class customer experience...